Results 81 to 90 of about 2,128 (111)

Post-COVID-19 Guillain-Barré Syndrome with GM1 and GD1b Antibodies: A Case Study and Literature Review. [PDF]

Am J Case Rep
Thiriveedi M, Sto Domingo FG, Longley S, Patel S, Baddam S, Chimakurthy A.   +5 more
europepmc   +1 more source

Nephrotic Syndrome: From Pathophysiology to Novel Therapeutic Approaches. [PDF]

Biomedicines
Frățilă VG, Lupușoru G, Sorohan BM, Obrișcă B, Mocanu V, Lupușoru M, Ismail G.   +6 more
europepmc   +1 more source

Thermooxidation of Four Sartans: Kinetic Analysis Based on Thermo-Gravimetric Data. [PDF]

Molecules
Ledeţi A, Baul B, Ridichie A, Ivan D, Vlase T, Tomoroga C, Dragomirescu A, Vlase G, Bertici RA, Man DE, Ledeţi I.   +10 more
europepmc   +1 more source

Effects of an oral vasopressin receptor antagonist (OPC‐31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone

Australian Veterinary Journal, 2000
ObjectiveThe syndrome of inappropriate secretion of antidiuretic hormone is a rare disorder in dogs characterised by hypo‐osmolality and persistent arginine vasopressin production in the absence of hypovolaemia and/or hypotension. The study describes the efficacy and safety of the nonpeptide selective arginine vasopressin V2receptor antagonist OPC ...
Fleeman, LM, Irwin, PJ, Phillips, PA, West, J   +3 more
openaire   +5 more sources

Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide

The American Journal of Medicine, 2001
SCOPUS: ar.j ; info:eu-repo/semantics ...
Guy Decaux
openaire   +4 more sources

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

European Journal of Clinical Pharmacology, 2011
Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases.
Gassanov, Natig, Semmo, Nasser, Semmo, Mariam, Nia, Amir M., Fuhr, Uwe, Er, Fikret   +5 more
openaire   +5 more sources

Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985

Journal of Laboratory and Clinical Medicine, 2001
VPA-985 is an orally active, competitive vasopressin V(2) receptor antagonist that in normal human beings increases water excretion without affecting solute excretion. Whether solute excretion is affected in patients with hyponatremia resulting from inappropriate secretion of antidiuretic hormone (SIADH) or from cirrhosis treated with VPA-985 is ...
G. Decaux
openaire   +4 more sources

Vasopressin V2 receptor antagonists for the syndrome of inappropriate antidiuretic hormone secretion

International Urology and Nephrology, 2023
Masayuki Tanemoto
openaire   +3 more sources

186 Use of tolvaptan, a new V2 receptor antagonist, in the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH) secondary to small cell lung cancer (SCLC) – a case series

Lung Cancer, 2014
N. Dorey, Elizabeth Toy, A.M. Brooke, I.M. Fraser   +3 more
openaire   +3 more sources